Beyond SGLT2 Inhibitors: Why Non-Steroidal MRAs Are Becoming the Third Pillar of Kidney Protection

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) are becoming an essential part of diabetes care, particularly for people with chronic kidney disease. Finerenone, the first approved non-steroidal MRA, complements SGLT2 inhibitors by targeting inflammation and fibrosis that continue to damage the kidneys despite standard therapy. Rather than replacing existing therapies, these agents work alongside them to provide more comprehensive cardiorenal protection.

Table of Contents

• Why diabetic kidney disease still progresses
• How non-steroidal MRAs protect the kidneys in diabetes
• Clinical evidence for finerenone in diabetic kidney disease
• Where non-steroidal MRAs fit into treatment guidelines
• Practical considerations for clinicians
• Conclusion
• Frequently Asked Questions

Why Diabetic Kidney Disease Continues to Progress

Diabetic kidney disease (DKD) remains the leading cause of chronic kidney disease (CKD) and kidney failure worldwide. Although strict glucose management delays complications, many patients continue to lose kidney function over time.

One reason is that chronic hyperglycemia triggers multiple biological pathways beyond elevated blood sugar alone. Persistent activation of the mineralocorticoid receptor promotes inflammation, oxidative stress, endothelial dysfunction, and tissue fibrosis throughout both the kidneys and cardiovascular system. Consequently, structural damage may continue even after blood pressure and HbA1c improve.

Renin-angiotensin system (RAS) blockade with ACE inhibitors or ARBs has long been the foundation of treatment. Later, SGLT2 inhibitors demonstrated significant reductions in CKD progression by lowering intraglomerular pressure and improving renal hemodynamics. GLP-1 receptor agonists further reduced cardiovascular risk while offering modest renal benefits.

Even so, residual risk remains substantial. Therefore, investigators have focused on therapies that specifically interrupt inflammatory and fibrotic signaling. This is precisely where non-steroidal MRAs for diabetes management offer a unique advantage.

How Non-Steroidal MRAs Protect the Kidneys in Diabetes

Mineralocorticoid receptors regulate sodium balance, blood pressure, and tissue remodeling. Excessive activation of these receptors contributes to chronic inflammation and fibrosis within the kidneys and heart.

Traditional steroidal MRAs such as spironolactone and eplerenone effectively block these receptors but often cause adverse effects, including hyperkalemia, gynecomastia, and hormonal side effects that limit long-term use.

Non-steroidal MRAs were developed to overcome many of these limitations. Finerenone, the first approved agent in this class, binds the mineralocorticoid receptor with high selectivity while producing more balanced tissue distribution. As a result, it delivers potent anti-inflammatory and anti-fibrotic effects with fewer endocrine adverse events.

Unlike SGLT2 inhibitors, which primarily influence glomerular hemodynamics, finerenone directly reduces inflammatory cytokine production, macrophage activation, oxidative stress, and collagen deposition. These complementary mechanisms explain why combining therapies may provide greater protection than either approach alone.

This multidimensional strategy has positioned non-steroidal MRAs as an increasingly important component of diabetes-related CKD management.

Clinical Evidence for Finerenone in Diabetic Kidney Disease

The growing enthusiasm surrounding finerenone is supported by several landmark randomized clinical trials.

The FIDELIO-DKD trial demonstrated that finerenone significantly reduced kidney disease progression and lowered cardiovascular events in patients with CKD associated with type 2 diabetes. Participants experienced slower declines in estimated glomerular filtration rate (eGFR) and fewer cases of kidney failure compared with placebo.

Subsequently, the FIGARO-DKD trial expanded these findings by showing meaningful reductions in cardiovascular outcomes, particularly hospitalization for heart failure, across patients with earlier stages of CKD.

Pooled analyses from the FIDELITY program confirmed that finerenone consistently reduces both kidney and cardiovascular complications across a broad spectrum of patients with diabetic kidney disease.

Importantly, many participants were already receiving guideline-directed therapies, including ACE inhibitors or ARBs. As SGLT2 inhibitor use increased during later analyses, evidence suggested additive rather than redundant benefits.

Current research is also evaluating finerenone alongside GLP-1 receptor agonists and newer combination treatment strategies, reflecting the growing movement toward layered cardiorenal protection.

According to the American Diabetes Association (ADA) and the KDIGO Clinical Practice Guideline, eligible patients with persistent albuminuria despite optimized RAS blockade should be considered for finerenone to reduce CKD progression and cardiovascular events.

Incorporating Non-Steroidal MRAs into Clinical Practice

Selecting the appropriate patient is essential for maximizing benefit while minimizing risk.

Most candidates have type 2 diabetes, CKD with persistent albuminuria, preserved serum potassium levels, and are already receiving maximally tolerated ACE inhibitor or ARB therapy. Many also benefit from concurrent SGLT2 inhibitor treatment.

Before initiating finerenone, clinicians should evaluate kidney function and serum potassium. Ongoing monitoring remains important because hyperkalemia, although less frequent than with steroidal MRAs, can still occur.

Rather than viewing treatment as a choice between drug classes, experts increasingly recommend layering therapies based on complementary mechanisms.

A practical sequence may include:

• Optimize blood pressure with ACE inhibitors or ARBs.
• Add an SGLT2 inhibitor whenever appropriate.
• Introduce finerenone for persistent albuminuria and residual cardiorenal risk.
• Consider GLP-1 receptor agonists when additional glycemic control, cardiovascular protection, or weight reduction is indicated.

This integrated approach aligns with modern CKD management, where multiple therapies address different disease pathways simultaneously instead of relying on a single intervention.

As evidence continues to evolve, non-steroidal MRAs for people with diabetes are expected to play an even greater role in slowing kidney disease progression while improving cardiovascular outcomes.

As clinicians adopt more comprehensive cardiorenal treatment strategies, finerenone and other non-steroidal MRAs are likely to become standard components of diabetic kidney disease management.

Conclusion

The management of diabetic kidney disease has entered a new era. While SGLT2 inhibitors and GLP-1 receptor agonists remain foundational therapies, they do not eliminate the inflammatory and fibrotic processes responsible for ongoing kidney damage. Non-steroidal MRAs, particularly finerenone, fill this critical therapeutic gap by targeting mineralocorticoid receptor activation and reducing both renal and cardiovascular risk. As current guidelines increasingly recommend layered treatment strategies, clinicians should become familiar with identifying appropriate candidates, monitoring therapy safely, and integrating these agents into comprehensive cardiorenal care. For many patients with CKD and type 2 diabetes, this third pillar may represent the next important step toward preserving kidney function and improving long-term outcomes.

Frequently Asked Questions

What are non-steroidal MRAs?

Non-steroidal mineralocorticoid receptor antagonists are medications that selectively block mineralocorticoid receptors to reduce inflammation and fibrosis without many of the hormonal side effects associated with older steroidal MRAs.

How is finerenone different from spironolactone?

Finerenone is more selective for the mineralocorticoid receptor and has a lower incidence of endocrine adverse effects such as gynecomastia, while still providing strong kidney and cardiovascular protection.

Can finerenone be combined with SGLT2 inhibitors?

Yes. Current evidence suggests that finerenone and SGLT2 inhibitors have complementary mechanisms and may provide additive cardiorenal benefits when used together in appropriate patients.

Who should receive non-steroidal MRAs?

Patients with type 2 diabetes, chronic kidney disease, persistent albuminuria, and optimized ACE inhibitor or ARB therapy are the primary candidates, provided kidney function and potassium levels are appropriate.

What monitoring is required after starting finerenone?

Serum potassium and kidney function should be checked before initiation and monitored periodically afterward to detect hyperkalemia or changes in renal function early.

Disclaimer: This article is intended for educational purposes only and should not replace individualized clinical judgment. Healthcare professionals should consult current prescribing information and evidence-based guidelines when making treatment decisions.